Watch for initial VEPPANU sales in Q3 2026 as the first commercial PROTAC; R289 Phase 1b data by year-end could be a catalyst. The raised revenue guidance implies confidence in core product growth, but cash burn from the $70M upfront payment merits monitoring for potential capital needs.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $40.48entry
- T+1 · 3mo ago −3.11%α −2.95% · $39.22
- T+5 · 3mo ago +3.43%α +3.08% · $41.87
- T+20 · 3mo ago +22.09%α +22.69% · $49.42
- T+60 · 19d ago +25.79%α +25.60% · $50.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EPS of $0.88, missing consensus of $0.91 by 3.3%. The company raised full-year 2026 revenue guidance to $285-295M (from $275-290M), reflecting strong core product sales momentum. The in-license of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2- breast cancer, expands the commercial portfolio, but the $70M upfront payment drew down cash to $95.3M from $155M at year-end 2025.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues of $78.7M (net product sales $67.0M + contract revenue $11.7M)
- Product sales grew 14% YoY; TAVALISSE +18%, REZLIDHIA +27%; GAVRETO -10%
- GAAP diluted EPS $0.88 (consensus $0.91), 3.3% miss
- Raised 2026 revenue guidance to $285-295M from prior $275-290M
- In-licensed VEPPANU (vepdegestrant) from Arvinas/Pfizer; U.S. launch expected mid-August
- Cash and investments $95.3M vs $155.0M at Dec 2025, after $70M upfront payment for VEPPANU
- R289 Phase 1b in lower-risk MDS on track for dose selection and preliminary data by year-end 2026
- Net income of $17.3M vs $59.6M in Q2 2025 (prior year included $40M non-cash Lilly revenue release)
Financial Impact
EPS miss of ~$0.03 vs consensus (-3.3%) but raised revenue guidance by ~$7.5M at midpoint; VEPPANU launch could add incremental revenue in H2 2026
Risk Factors
- VEPPANU commercial launch uncertainty and competition in ER+/HER2- metastatic breast cancer
- GAVRETO net product sales declining 10% YoY
- Cash drawdown to $95.3M may require future financing if operating cash flow turns negative
- Phase 1b R289 data may not meet expectations
- Dependence on TAVALISSE for ~60% of product sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000053 |
| Document: 0001034842-26-000053-index.html | 0001034842-26-000053 |
| Document: 0001034842-26-000053.txt | 0001034842-26-000053 |
| 8-K Data (Synthetic) | 0001034842-26-000053 |
Track record
12 reports on RIGL
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Viewing Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers